Zacks Investment Research
30 Oct 2026, 17:50 UTC · 1h ago
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
Impact · against what's priced in
Exelixis' Q3 beat is largely a confirmation of current market expectations. While the growth in Cabometyx sales is strong, the current stock price already assumes these demand levels and revenue growth rates, leaving little room for a catalyst.
- EXEL+0.00
Already priced in
- The price assumes
Current CABOMETYX demand driving 10% year-over-year revenue growth
The reported 10.2% year-over-year revenue growth and the $603.2 million in Cabometyx sales align almost exactly with the 10% growth rate the market price already assumes.
What EXEL's price assumes · Sep 4
Top 2 movers · tap to explore
